First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.
Extensive Stage Small Cell Lung Cancer
DRUG: Tarlatamab|DRUG: Carboplatin|DRUG: Etoposide|DRUG: Atezolizumab|DRUG: Durvalumab
Number of Participants with a Dose Limiting Toxicity (DLT), 24 months|Number of Participants with Treatment-emergent Adverse Events (TEAE), 24 months|Number of Participants with Treatment-related Adverse Events, 24 months|Number of Participants with Clinically Significant Changes in Vital Signs, 24 months|Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG) Measurements, 24 months|Number of Participants with Clinically Significant Changes in Clinical Laboratory Tests, 24 months
6-month Progression-free Survival (PFS), 24 months|Objective Response (OR), Per modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, 24 months|Duration of Response (DOR), 24 months|Disease Control Rate(DCR), 24 months|Overall Survival (OS), 24 months|Serum Concentration of Tarlatamab, 24 months
This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.